Baader Bank Aktiengesellschaft Has $515,000 Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)

Baader Bank Aktiengesellschaft trimmed its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 33.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,700 shares of the company’s stock after selling 3,300 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in GeneDx were worth $515,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Barclays PLC grew its position in shares of GeneDx by 346.3% during the 3rd quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after purchasing an additional 14,681 shares in the last quarter. Chartwell Investment Partners LLC bought a new position in shares of GeneDx in the third quarter worth approximately $1,722,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after acquiring an additional 110,666 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of GeneDx in the 3rd quarter worth about $325,000. Finally, Lisanti Capital Growth LLC bought a new stake in GeneDx in the 3rd quarter worth approximately $1,554,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at GeneDx

In other news, CEO Katherine Stueland sold 23,108 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84. Following the sale, the chief executive officer now directly owns 82,318 shares in the company, valued at approximately $5,801,772.64. This trade represents a 21.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $70.78, for a total transaction of $8,973,629.96. Following the transaction, the insider now owns 2,719,692 shares of the company’s stock, valued at approximately $192,499,799.76. The trade was a 4.45 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 361,737 shares of company stock worth $27,909,458. Corporate insiders own 27.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on WGS shares. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Craig Hallum lifted their price target on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their target price on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their price objective on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $70.67.

GeneDx Stock Up 2.9 %

GeneDx stock opened at $77.86 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The firm has a market cap of $2.14 billion, a P/E ratio of -25.04 and a beta of 2.02. GeneDx Holdings Corp. has a twelve month low of $3.62 and a twelve month high of $98.87. The business has a fifty day moving average of $78.37 and a two-hundred day moving average of $57.69.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The business’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.82) EPS. On average, analysts forecast that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.